Scientists at both Dana-Farber Cancer Institute and Boston Children’s Hospital are conducting numerous research studies to better clinicians' understanding and treatment of brain tumors and gliomas. Our research program offers patients unparalleled access to clinical trials, in which children can receive the newest treatments. We are consistently one of the most well-funded pediatric brain tumor centers in the United States, and we pride ourselves on rapidly bringing our discoveries to the aid of our patients.
Dana-Farber/Boston Children's houses the Pediatric Low-Grade Astrocytoma (PLGA) Program, the world's only multidisciplinary clinical and research program dedicated to pediatric low-grade gliomas. Established in 2007 with support from the PLGA Foundation, the program takes a multifaceted approach to finding more effective, less toxic treatments and a cure for children battling brain tumors, and has become the standard bearer for the research and care of pediatric brain tumors. Our pediatric neuro-oncologists, including Pratiti (Mimi) Bandopadhayay, MBBS, PhD, are actively contributing to these efforts. Our program has contributed to international research efforts that have identified genomic drivers that contribute to the growth of pilocytic astrocytoma. Specifically, we have identified genes that are commonly mutated in pilocytic astrocytoma. These findings are guiding clinical trials examining the activity of new drugs specifically for children with optic nerve glioma.
Clinical trials
Clinical trials, or research studies evaluating new treatment approaches, are a major offering at Dana-Farber/Boston Children’s. Clinical trials are very important for children with hard-to-treat or relapsed conditions.
It’s possible that your child will be eligible to participate in one of the Glioma Program’s current brain tumor clinical trials. In addition to launching our own clinical trials, we also offer trials available through collaborative groups such as the Children's Oncology Group (COG) and the Pacific Pediatric Neuro-Oncology Consortium (PNOC). We are also the New England Phase I Center of the Children's Oncology Group. If your child has a progressive or recurrent tumor, they may be eligible for a number of experimental therapies available through these groups or from one of our independent clinical investigators.